Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with Wegovy LIMITATIONS OF USE According to the package insert, Wegovy should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist safety and efficacy in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established has not been studied in patient with a history of pancreatitis WARNINGS AND PRECAUTIONS The safety profile of semaglutide in the treatment of obesity has been investigated through several clinical trials
However, this doesnt mean youll see weight loss results immediately
Reviewed by Julia Bailey, UGA Dietetic Intern References Mayo Clinic Staff
Your treatment is dispensed following an online consultation and prescriber approval
In the first week, you will start observing changes in your physiology like changes in your hunger routine and some differences in weight
family planning or smoking cessation)
